Abstract
Objectives: Congenital heart defect (CHD) represents almost 33% of all major congenital deformities, representing a worldwide health problem. The aim of the study is to identify the value of lecithin, cephalin, sphingomyelin & other phospholipids screening in the pathogenesis and prognosis of CHDs and consequently improve their management. Methods: A total of 89 child with CHDs were included [35 atrial septal defect (ASD), 27 ventricular septal defect (VSD) and 27 patent ductus arteriosus (PDA)] and 34 child as a control group. Biochemical analysis of the plasma levels of total and different component of phospholipids for both CHD and control group were done by colorimetry and two-dimensional thin layer chromatography. Assay of plasma L-carnitine level was done by ELISA for both patients and control group. Results:The overall results of the present study revealed a significant reduction in the total phospholipids among CHD patients in comparison to the control group; also, a significant change in the phospholipid profile. A significant lower plasma L-carnitine levels in the CHDs group when compared with the control group (p < 0. 001). Conclusions: Disturbed total and differential types of phospholipids &plasma L-carnitine levels occurs in children with CHDs. Moreover, cell-specific targeting of L-carnitine and phospholipid biosynthetic pathways might serve as a possible strategy for helping favorable outcome in management of CHDs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have